Press release
Leiomyosarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Leiomyosarcoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Leiomyosarcoma Pipeline Outlook [https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Leiomyosarcoma Pipeline Report
* In February 2025:- PharmaMar - The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
* In February 2025:- Atara Biotherapeutics :- The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases. This is a multicenter, multicohort, open-label, single-arm, Phase 2 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases
* DelveInsight's Leiomyosarcoma Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
* The leading Leiomyosarcoma Companies such as Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
* Promising Leiomyosarcoma Therapies such as Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, Dinutuximab Beta, Zoledronic acid, Interleukin-2, and others.
Stay ahead with the most recent pipeline outlook for Leiomyosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Leiomyosarcoma Approved Drugs [https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Leiomyosarcoma Emerging Drugs Profile
* ADI PEG20: Polaris Group
ADI-PEG 20 is a first-in-class therapeutic approach to deplete arginine and starve cancer cells. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, some cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient's normal cells unharmed. Currently, it is in Phase III stage of clinical trial evaluation to treat Leiomyosarcoma.
* OR2805: OncoResponse
OR2805 is a fully human monoclonal antibody that targets CD163, an immune-suppressive receptor highly expressed on tumor-associated macrophages (TAMs). It was discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy and is designed to reverse the immunosuppressive effect of TAMs, enhancing anti-tumor T-cell responses. In preclinical studies, OR2805 showed significant anti-tumor activity in lung cancer xenograft models in humanized mice and relieved the suppressive effect of M2c macrophages in coculture assays. OR2805 is currently being evaluated in a Phase I/II clinical trial to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with Leiomyosarcoma. The trial includes a dose-escalation phase, expansion cohorts, and a biology cohort to evaluate potential biomarkers. OR2805 has the potential to improve anti-tumor T-cell responses by reversing the immunosuppressive effect of TAMs, making it a promising therapeutic strategy for treating advanced cancers.
The Leiomyosarcoma pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Leiomyosarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leiomyosarcoma Treatment.
* Leiomyosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Leiomyosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leiomyosarcoma market.
Explore groundbreaking therapies and clinical trials in the Leiomyosarcoma Pipeline. Access DelveInsight's detailed report now! @ Leiomyosarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Leiomyosarcoma Companies
Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Leiomyosarcoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Leiomyosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Leiomyosarcoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Leiomyosarcoma Pipeline Report
* Coverage- Global
* Leiomyosarcoma Companies- Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
* Leiomyosarcoma Therapies- Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, Dinutuximab Beta, Zoledronic acid, Interleukin-2, and others.
* Leiomyosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* LeiomyosarcomaTherapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Leiomyosarcoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Leiomyosarcoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Leiomyosarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Leiomyosarcoma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Leiomyosarcoma Collaboration Deals
* Late Stage Products (Phase III)
* AL-3818: Advenchen Laboratories
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* OR2805: OncoResponse
* Drug profiles in the detailed report.....
* Inactive Products
* Leiomyosarcoma Key Companies
* Leiomyosarcoma Key Products
* Leiomyosarcoma- Unmet Needs
* Leiomyosarcoma- Market Drivers and Barriers
* Leiomyosarcoma- Future Perspectives and Conclusion
* Leiomyosarcoma Analyst Views
* Leiomyosarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=leiomyosarcoma-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leiomyosarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3895326 • Views: …
More Releases from ABNewswire
Dr. Zenovia Bryant-Bright Announces Upcoming Memoir: A Black Love Story of Loss, …
Image: https://www.abnewswire.com/upload/2026/01/45ff470dbcae7669354b6505319ce953.jpg
United States - Dr. Zenovia Bryant-Bright announces the release of her highly anticipated memoir, A Black Love Story of Loss, and Life After the Military , arriving January 26, 2026. This deeply personal and courageous book is more than a collection of memories, it is a testimony of survival, strength, love, and truth.
Too often, the stories of Black women who have served in the military are erased, dismissed, or…
GetInsuredTexas.com Launches as the Essential Guide to Texas Insurance Policies, …
GetInsuredTexas.com, a new website from Baxter Insurance Agency, Inc., is now live, offering a one-stop shop for Texans to navigate the complexities of the state's insurance market, from understanding policies to comparing companies.
HOUSTON, TX - Jan 11, 2026 - Baxter Insurance Agency, Inc., a trusted name in the Texas insurance industry for over 40 years, is proud to announce the launch of GetInsuredTexas.com. This new platform is designed to be…
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
More Releases for Leiomyosarcoma
Leiomyosarcoma Market Growing at a CAGR of around 6.3%
Leiomyosarcoma Market
The Leiomyosarcoma Market was valued at ~USD 1.05 billion in 2024 and is projected to reach ~USD 1.92 billion by 2034, growing at a CAGR of around 6.3%. Growth is driven by rising incidence of soft tissue sarcomas, improved diagnostic imaging, and wider use of targeted and combination oncology therapies.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71230
Key Market Drivers
• Growing detection of uterine and non-uterine leiomyosarcoma through improved…
Uterine Leiomyosarcoma Market is expected to reach USD 1.2 billion by 2034
Uterine leiomyosarcoma (uLMS) is a rare but highly aggressive subtype of soft tissue sarcoma that originates in the smooth muscle layer of the uterus. Unlike benign fibroids, uLMS is often diagnosed at advanced stages and is associated with poor prognosis, high recurrence rates, and limited treatment options. Representing less than 1% of all uterine cancers, it nevertheless accounts for a disproportionate share of mortality in gynecologic oncology.
Download Full PDF Sample…
Leiomyosarcoma Drug Market Estimated to Experience a Hike in Growth by 2033
The Leiomyosarcoma Drug Market was valued at USD 0.72 billion in 2023, and it is projected to reach USD 1.55 billion by 2033, growing at a CAGR of 8.0% from 2024 to 2033.
Leiomyosarcoma Drug Market Overview
The Leiomyosarcoma Drug Market is expanding due to the increasing prevalence of soft tissue sarcomas and advancements in oncology therapeutics. Leiomyosarcoma, a rare but aggressive cancer, has driven demand for more effective and targeted treatments.…
Leiomyosarcoma Clinical Trials, Treatment Drugs, Emerging Drugs, and Companies 2 …
DelveInsight's, "Leiomyosarcoma Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Leiomyosarcoma Pipeline. Dive…
Leiomyosarcoma Treatment Market is expected to reach USD 834.12 million by 2030
Global leiomyosarcoma treatment market has experienced significant growth due to the increased prevalence of soft tissue sarcomas is one of the driving factors for the global leiomyosarcoma treatment market. For instance, in the U.S., total new cases diagnosed for soft tissue sarcomas are 13,460 and 5,350 people which are expected to die from this type of cancer. Increase in women population having fibroids may have the chances to develop LMS…
Leiomyosarcoma Pipeline | Clinical Trials, Key Companies- Merck, PTC Therapeutic …
DelveInsight's, "Leiomyosarcoma - Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download Sample Report to learn more @https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Leiomyosarcoma Overview
Leiomyosarcoma is a type of…
